European Consumer Staples in China Report Interpretation

Overview

Based on meetings with multinational and local consumer companies, consultants and media representatives in Shanghai, Barclays sees a structurally challenging China market but identifies premium and masstige as the most attractive growth areas for European consumer staples companies.

Core views

Barclays' central conclusion is that China remains a difficult consumer market: weak sentiment, subdued equity markets and the unresolved property downturn point to a challenging second half, while retail spending fell year on year in July after being broadly flat in June. The consumer base is becoming more polarised, with lower- and middle-income consumers, particularly outside tier-one cities, under greater pressure while higher-income consumers in Shanghai and Shenzhen appear more resilient. Younger consumers are especially demanding because their spending power is constrained, they are accustomed to e-commerce promotions and expect constant product newness. Premium and masstige are the principal exceptions to the weak backdrop. Barclays says premium and prestige beauty have driven category recovery since Q2, and super-premium products have gained share in infant milk formula (IMF). Higher-income spending has been more resilient, while wellness and longevity are taking a larger share of wallet. By contrast, mainstream volumes may benefit from trading down, but value growth is likely to be capped by severe local-brand price competition and promotions, particularly as Douyin and Pinduoduo grow. Barclays therefore argues that European consumer-staples companies should focus investment on premium and masstige rather than pursue costly mainstream-market competition with more limited returns. Premium positioning now requires more than heritage or price. Consumers increasingly scrutinise ingredients and efficacy, and younger consumers expect rapid results, particularly in beauty where procedures and devices have raised expectations. Barclays argues that brands need innovation and demonstrable scientific credibility to earn a premium. Local brands can move faster, but their more limited fundamental-research investment may constrain premium competition. International companies that combine long-term science with quicker innovation cycles are viewed as better placed. The speed gap remains material: industry experts cited local skincare innovation cycles of 3-24 months versus 24-60 months for international companies. China's channel mix is shifting rapidly. Douyin and Xiaohongshu are important for discovery, education and visibility, while Tmall and JD.com are better positioned for repeat conversion; Tmall supports authenticity perceptions and JD.com offers reliable delivery. Douyin is the fastest-growing platform and is important for reaching younger women, but traffic, platform, KOL, fulfilment and returns costs make profitable selling difficult. Barclays expects Tmall and JD.com to remain relevant despite lost share, citing their improving competitiveness and superior unit economics. Xiaohongshu has influence in inspiration and education but its logistics and transaction capabilities limit conversion. Local Chinese brands benefit from manufacturing costs, OEM experience, rapid product iteration, direct consumer feedback and superior social-commerce familiarity. Barclays cautions that international companies can misread lower-tier-city weakness and underestimate volatility after becoming accustomed to China's earlier growth cycle. IMF is an exception because Chinese-label products require SAMR registration and technical review, allowing international brands to lead innovation through English-label products. Among covered companies, Barclays sees L'Oréal as well placed to gain share through premium skincare, citing strong China performance from Helena Rubinstein, SkinCeuticals, La Roche-Posay and YSL. It sees Unilever's premiumisation of Dove, Vaseline and Lux as supporting a sustainable turnaround; management reported a return to mid-single-digit China growth, driven by share gains rather than market expansion. Danone's Essensis premiumisation strategy is expected to drive IMF growth and more than offset declining birth rates, with the company underindexed in super-premium mix. Birth-rate subsidies have not improved the trend, and Barclays expects further declines, disproportionately affecting mainstream IMF below RMB200 per kg and contributing to specialist baby- and maternity-store closures. Unilever's China sales excluding Food are €1.7bn, comprising 36% Beauty & Wellness, 24% Personal Care and 40% Home Care. Online represents 45% of China sales; Douyin grew 25% and Pinduoduo 35%, though management characterises Douyin as lower margin but important for customer acquisition and brand building. Market growth slowed from about 2.5% in FY23 to below 1% in FY24/25, and management does not expect a near-term recovery. Barclays nevertheless highlights operational agility, faster fulfilment and focused Power Brands as important to competing in this environment.

Analysis framework

Barclays draws on a Shanghai field trip with multinational and local consumer companies, consultants and media representatives. It assesses the consumer backdrop, income polarisation, category demand, premiumisation, product-science requirements, platform economics, local-versus-international competitive capabilities, and company-specific execution in China.

Methodology notes

• Other

  Shanghai field-trip and stakeholder interviews

  Barclays bases its conclusions on meetings with consumer companies, specialist consultants and media representatives, using their observations to assess demand, channels, competition and company positioning.

• Industry AnalysisSupply-demand framework

  Consumer demand and category-growth assessment

  The report links weak sentiment, property-market uncertainty and income pressure to consumption, then distinguishes resilient premium demand from promotion-led mainstream demand.

• Competition & strategyValue chain analysis

  Channel and competitive-capability analysis

  The report compares discovery, conversion and fulfilment roles across platforms and contrasts local and international brands' speed, cost, research and execution capabilities.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• L'Oréal SA (OREP.PA)

  Premium skincare positioning is expected to support share gains in China.

  Strengths

  Helena Rubinstein, SkinCeuticals, La Roche-Posay and YSL were among the best-performing brands in China.

  Weaknesses

  International brands face slower innovation cycles than local competitors.

  Comparison

  Local brands generally have faster innovation cycles but may lack equivalent fundamental research.

  Risks

  Softer beauty-market recovery, execution shortfalls in white-space opportunities and lower-than-expected A&P savings.

• Unilever PLC (ULVR.AS / ULVR.L)

  Premiumisation of Power Brands and channel prioritisation underpin the China turnaround.

  Strengths

  Mid-single-digit growth has returned, supported by share gains; Vaseline continues to grow at double digits.

  Weaknesses

  China market growth is weak and Douyin is lower margin.

  Comparison

  Local competitors benefit from faster innovation, real-time consumer insights and small-batch testing.

  Risks

  Competitive share gains, weak European Food trends, FX exposure and failure to sustain Power Brand growth.

• Danone (DANO.PA)

  Premiumisation through Essensis is positioned as the core IMF growth driver.

  Strengths

  Underindexing in super-premium sales mix suggests growth opportunity.

  Weaknesses

  Declining births weigh on IMF volumes, particularly in mainstream products below RMB200 per kg.

  Comparison

  International brands retain an innovation advantage in IMF because Chinese-label products face tighter registration and technical-review requirements.

  Risks

  Higher protein and medical-nutrition capex, weaker operational leverage and over-reliance on China for growth.

Key data

• China retail spendingDeclined year on year in JulyAfter being broadly flat in June.
• China market growthc.2.5% in FY23; below 1% in FY24/25Unilever management does not expect a near-term recovery.
• Local versus international skincare innovation cycle3-24 months versus 24-60 monthsIndustry-expert comparison cited by Barclays.
• Unilever China sales excluding Food€1.7bn36% Beauty & Wellness, 24% Personal Care and 40% Home Care.
• Unilever online sales share in China45%Douyin grew 25% and Pinduoduo grew 35%.
• Unilever China growthMid-single digits year to dateSupported by market-share gains; Vaseline grew double digits.
• Unilever order dispatchMore than 90% within 10 hoursSupported by warehouse automation initiatives.

Impact & implications

Barclays argues that China exposure should be selective: premium and masstige categories, credible product science, faster innovation and disciplined use of digital channels are more important than broad mainstream expansion. The report identifies L'Oréal, Unilever and Danone as aligned with this approach.

Risks

• China's weak consumer sentiment, unresolved property downturn and subdued market growth may persist.
• Intense price competition and promotions could limit mainstream-category value growth.
• Local brands' faster innovation and social-commerce execution may pressure international brands.
• China's declining birth rate may further reduce mainstream infant milk formula volumes.

What to watch

• Whether premium and prestige beauty continue to lead category recovery.
• China retail demand, consumer sentiment and the pace of any market-growth recovery.
• The rate of birth-rate decline and further closures of specialist baby and maternity stores.
• Douyin's growth and profitability, alongside Tmall, JD.com and Xiaohongshu execution.
• Whether international brands can shorten innovation cycles while maintaining scientific differentiation.
• Unilever's ability to sustain share-led mid-single-digit China growth.